| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | CA2436899A1 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436847A1 Treatment of cancer by reduction of intracellular energy and pyrimidines |
| 06/13/2002 | CA2436692A1 Oral extended release formulation of gepirone |
| 06/13/2002 | CA2436666A1 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | CA2436662A1 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2436508A1 Liquid composition comprising an alcohol |
| 06/13/2002 | CA2436311A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2432549A1 Clear propofol compositions |
| 06/13/2002 | CA2431861A1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 06/13/2002 | CA2431374A1 Novel fibroblast growth factors |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431181A1 Nootropic effect enhancer |
| 06/13/2002 | CA2431171A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| 06/13/2002 | CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2431040A1 Substituted imidazopyridines |
| 06/13/2002 | CA2431032A1 6-0-carbamoyl ketolide derivatives of erythromycin useful as antibacterials |
| 06/13/2002 | CA2431005A1 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430951A1 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2430846A1 Substituted carboxylic acid derivatives |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430842A1 Process for making a thrombin inhibitor |
| 06/13/2002 | CA2430769A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | CA2430723A1 Method for precipitating red blood cells |
| 06/13/2002 | CA2430685A1 A substance or composition for the treatment of cancer |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430466A1 Klainetin and derivatives thereof, method for their production and the use of the same |
| 06/13/2002 | CA2430412A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430355A1 Tetralone derivatives as antitumor agents |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429727A1 Solid polyunsaturated fatty acid compositions |
| 06/13/2002 | CA2429258A1 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | CA2427430A1 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | CA2426988A1 Multicomponent compositions containing chitosan and methods of preparing same |
| 06/13/2002 | CA2426158A1 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 06/13/2002 | CA2425396A1 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/12/2002 | EP1213300A1 Novel human androgen receptor variants |
| 06/12/2002 | EP1213296A1 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 06/12/2002 | EP1213291A1 Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213285A2 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors |
| 06/12/2002 | EP1213282A1 Substituted imidazolium salts and their use for the inhibition of protein ageing. |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1213031A2 Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist |
| 06/12/2002 | EP1213029A1 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| 06/12/2002 | EP1213026A1 Brain cell or nerve cell protecting agents comprising ginseng |
| 06/12/2002 | EP1213021A1 Remedies for diabetes |
| 06/12/2002 | EP1213020A2 Pharmaceutical compositions having appetite suppressant activity |
| 06/12/2002 | EP1213019A2 Method for treating chronic obstructive pulmonary disease |
| 06/12/2002 | EP1213018A1 Preventive and therapeutic agents for eye diseases |
| 06/12/2002 | EP1213017A2 Use of a 5-HT2C receptor agonist for the treatment of hot flushes |
| 06/12/2002 | EP1213015A1 Oral pharmaceutical composition with delayed release of proton pump inhibitors |
| 06/12/2002 | EP1213014A2 Process and system for controlled-release drug delivery |
| 06/12/2002 | EP1212616A2 Inhibitors of binding between proteins and macromolecular ligands |
| 06/12/2002 | EP1212464A2 Diagnostics and therapeutics for osteoporosis |
| 06/12/2002 | EP1212456A1 Antisense modulation of shp-2 expression |
| 06/12/2002 | EP1212455A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 06/12/2002 | EP1212453A1 Method to identify gene function using small molecule probes |
| 06/12/2002 | EP1212428A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 06/12/2002 | EP1212416A2 Nucleic acid based modulators of gene expression |
| 06/12/2002 | EP1212408A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212376A1 Synthetic vegetal melanins, process for their production and compositions containing thereof |
| 06/12/2002 | EP1212363A2 Il-16 antagonists |
| 06/12/2002 | EP1212362A2 Card proteins involved in cell death regulation |
| 06/12/2002 | EP1212359A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212346A1 Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds |
| 06/12/2002 | EP1212345A2 Orally active 7.alpha.-alkyl androgens |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212339A1 2'-o-acetamido modified monomers and oligomers |
| 06/12/2002 | EP1212337A1 Pesticidal macrolides |
| 06/12/2002 | EP1212336A2 Spherical telithromycin clusters, method for the production and use thereof in the preparation of pharmaceutical forms |
| 06/12/2002 | EP1212335A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 06/12/2002 | EP1212330A1 Androgen receptor modulator compounds and methods |
| 06/12/2002 | EP1212329A2 Amine derivatives of benzo[4,5]thieno[2,3-d]pyrimidine |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212326A1 PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS |
| 06/12/2002 | EP1212324A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 06/12/2002 | EP1212323A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/12/2002 | EP1212322A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/12/2002 | EP1212320A2 Phenylpiperazines as serotonin reuptake inhibitors |
| 06/12/2002 | EP1212319A2 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 06/12/2002 | EP1212318A1 Substituted indolinones as tyrosine kinase inhibitors |
| 06/12/2002 | EP1212317A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 06/12/2002 | EP1212316A2 Benzopyrans and benzothiopyrans as rar selective retinoid agonists |
| 06/12/2002 | EP1212315A1 Novel chalcones |